$DRUG

The FDA partially halted Bright Minds Biosciences' planned Phase 2 trial for BMB-101, citing mouse toxicity and insufficient data. The company awaits the FDA's full letter within 30 days.

Bright Minds Biosciences Inc is anticipated to report an earnings loss of C$1.19 per share. This information comes from an earnings preview, indicating financial analysts' expectations for the company's upcoming results. The article is a brief financial news item from Reuters.

Cormorant Global Healthcare Master Fund, LP, an entity associated with Cormorant Asset Management and Bihua Chen, sold 109,331 common shares of Bright Minds Biosciences Inc. (DRUG) at $89.50 per share in an open market transaction. This sale, totaling approximately $9.79 million, leaves the reporting structure with 950,000 common shares indirectly held. The involved parties disclaim beneficial ownership except for their pecuniary interest.

Cormorant Asset Management, LP and Bihua Chen have filed an Amended Passive Investment Disclosure (SCHEDULE 13G/A) for BRIGHT MINDS BIOSCIENCES INC. They report shared beneficial ownership of 950,000 common shares, representing 9.71% of the class. The filing indicates 9,787,161 Common Shares outstanding as of February 12, 2026, held through Cormorant Global Healthcare Master Fund, LP.

HC Wainwright has increased its price target for Bright Minds Biosciences (NASDAQ:DRUG) to $145 from $115, maintaining a "buy" rating and suggesting an 82% upside. The company's stock currently trades around $79.60 with a market cap of $774.5 million and an average analyst consensus of "Moderate Buy" with a $124.50 target. This comes after Bright Minds Biosciences reported a quarterly EPS of -$0.70, beating analyst estimates, and is progressing with its lead oral candidate BMB-101.

Short interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) increased by 67.5% to 564,277 shares as of January 15th, representing 10.1% of shares short and a 1.6-day days-to-cover ratio. Analysts have a "Moderate Buy" rating with an average target price of $121.00, while the stock recently traded at $77.75. Institutional ownership is significant at 40.52%, with JPMorgan Chase & Co. notably increasing its holdings.

Bright Minds Biosciences (NASDAQ: DRUG) launched a public offering to raise US$100 million through common shares and pre-funded warrants, with an additional 15% underwriters' option. The proceeds will fund clinical trials for absence seizures, developmental and epileptic encephalopathy (DEE), and Prader-Willi syndrome, as well as initiating Phase 1 trials for BMB-105. This offering aims to advance the company's research and development in neurological and psychiatric disorders.

U.S. stocks saw gains on Tuesday, with several companies experiencing significant surges. Microchip Technology Inc. (NASDAQ: MCHP) rose after revising its fiscal third-quarter revenue expectations upwards, while Alumis Inc. (NASDAQ: ALMS) jumped following positive Phase 3 trial results for its psoriasis treatment. Other notable movers included Aeva Technologies Inc. (NASDAQ: AEVA), Terrestrial Energy Inc. (NASDAQ: IMSR), and Bright Minds Biosciences Inc. (NASDAQ: DRUG), all posting strong gains due to significant corporate developments.

Bright Minds Biosciences (NASDAQ:DRUG) experienced a 5.4% drop in share price on Thursday, trading as low as $83.66 with reduced midday volume. Despite a consensus "Buy" rating from analysts with varied price targets, the stock has seen increased institutional investment, with firms like Braidwell and Vivo Capital acquiring new or expanded stakes. The company, focused on developing therapeutics for severe diseases, has a market cap of $632.8 million and a negative P/E ratio.

Eight brokerages have issued a "Buy" consensus recommendation for Bright Minds Biosciences Inc. (NASDAQ:DRUG), with an average one-year target price of $82.50. The company's stock opened at $88.83 and has a market capitalization of $691.95 million. Institutional investors own 40.52% of the company's stock, with several firms